JP2016094451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016094451A5 JP2016094451A5 JP2015246589A JP2015246589A JP2016094451A5 JP 2016094451 A5 JP2016094451 A5 JP 2016094451A5 JP 2015246589 A JP2015246589 A JP 2015246589A JP 2015246589 A JP2015246589 A JP 2015246589A JP 2016094451 A5 JP2016094451 A5 JP 2016094451A5
- Authority
- JP
- Japan
- Prior art keywords
- nmol
- hour
- composition
- naglu
- fold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35885710P | 2010-06-25 | 2010-06-25 | |
| US61/358,857 | 2010-06-25 | ||
| US36078610P | 2010-07-01 | 2010-07-01 | |
| US61/360,786 | 2010-07-01 | ||
| US38786210P | 2010-09-29 | 2010-09-29 | |
| US61/387,862 | 2010-09-29 | ||
| US201161435710P | 2011-01-24 | 2011-01-24 | |
| US61/435,710 | 2011-01-24 | ||
| US201161442115P | 2011-02-11 | 2011-02-11 | |
| US61/442,115 | 2011-02-11 | ||
| US201161476210P | 2011-04-15 | 2011-04-15 | |
| US61/476,210 | 2011-04-15 | ||
| US201161495268P | 2011-06-09 | 2011-06-09 | |
| US61/495,268 | 2012-06-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516847A Division JP6063380B2 (ja) | 2010-06-25 | 2011-06-25 | サンフィリポ症候群ｂ型の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016094451A JP2016094451A (ja) | 2016-05-26 |
| JP2016094451A5 true JP2016094451A5 (cg-RX-API-DMAC10.html) | 2016-09-08 |
Family
ID=45352777
Family Applications (22)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236539A Active JP6250616B2 (ja) | 2010-06-25 | 2015-12-03 | 治療薬のｃｎｓ送達 |
| JP2015246244A Active JP6285409B2 (ja) | 2010-06-25 | 2015-12-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246589A Pending JP2016094451A (ja) | 2010-06-25 | 2015-12-17 | サンフィリポ症候群ｂ型の処置 |
| JP2015246258A Withdrawn JP2016040335A (ja) | 2010-06-25 | 2015-12-17 | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246952A Active JP6346162B2 (ja) | 2010-06-25 | 2015-12-18 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017177784A Active JP6466538B2 (ja) | 2010-06-25 | 2017-09-15 | 治療薬のｃｎｓ送達 |
| JP2017194348A Active JP6522072B2 (ja) | 2010-06-25 | 2017-10-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2017194508A Active JP6522073B2 (ja) | 2010-06-25 | 2017-10-04 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2018192589A Active JP6797876B2 (ja) | 2010-06-25 | 2018-10-11 | 治療薬のｃｎｓ送達 |
| JP2018226358A Active JP6898909B2 (ja) | 2010-06-25 | 2018-12-03 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2018227369A Active JP6938456B2 (ja) | 2010-06-25 | 2018-12-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2020000930A Withdrawn JP2020079244A (ja) | 2010-06-25 | 2020-01-07 | 治療薬のｃｎｓ送達 |
| JP2020023620A Pending JP2020079297A (ja) | 2010-06-25 | 2020-02-14 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2020024183A Pending JP2020079298A (ja) | 2010-06-25 | 2020-02-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021115564A Active JP7087175B2 (ja) | 2010-06-25 | 2021-07-13 | 治療薬のｃｎｓ送達 |
| JP2021115560A Active JP7448507B2 (ja) | 2010-06-25 | 2021-07-13 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2021133184A Active JP7591476B2 (ja) | 2010-06-25 | 2021-08-18 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021196898A Active JP7359827B2 (ja) | 2010-06-25 | 2021-12-03 | 治療薬のｃｎｓ送達 |
| JP2023014814A Active JP7543459B2 (ja) | 2010-06-25 | 2023-02-02 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2023024170A Pending JP2023062114A (ja) | 2010-06-25 | 2023-02-20 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2023078673A Pending JP2023099216A (ja) | 2010-06-25 | 2023-05-11 | 治療薬のｃｎｓ送達 |
| JP2024069806A Ceased JP2024097029A (ja) | 2010-06-25 | 2024-04-23 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236539A Active JP6250616B2 (ja) | 2010-06-25 | 2015-12-03 | 治療薬のｃｎｓ送達 |
| JP2015246244A Active JP6285409B2 (ja) | 2010-06-25 | 2015-12-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
Family Applications After (19)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015246258A Withdrawn JP2016040335A (ja) | 2010-06-25 | 2015-12-17 | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246952A Active JP6346162B2 (ja) | 2010-06-25 | 2015-12-18 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017177784A Active JP6466538B2 (ja) | 2010-06-25 | 2017-09-15 | 治療薬のｃｎｓ送達 |
| JP2017194348A Active JP6522072B2 (ja) | 2010-06-25 | 2017-10-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2017194508A Active JP6522073B2 (ja) | 2010-06-25 | 2017-10-04 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2018192589A Active JP6797876B2 (ja) | 2010-06-25 | 2018-10-11 | 治療薬のｃｎｓ送達 |
| JP2018226358A Active JP6898909B2 (ja) | 2010-06-25 | 2018-12-03 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2018227369A Active JP6938456B2 (ja) | 2010-06-25 | 2018-12-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2020000930A Withdrawn JP2020079244A (ja) | 2010-06-25 | 2020-01-07 | 治療薬のｃｎｓ送達 |
| JP2020023620A Pending JP2020079297A (ja) | 2010-06-25 | 2020-02-14 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2020024183A Pending JP2020079298A (ja) | 2010-06-25 | 2020-02-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021115564A Active JP7087175B2 (ja) | 2010-06-25 | 2021-07-13 | 治療薬のｃｎｓ送達 |
| JP2021115560A Active JP7448507B2 (ja) | 2010-06-25 | 2021-07-13 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2021133184A Active JP7591476B2 (ja) | 2010-06-25 | 2021-08-18 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021196898A Active JP7359827B2 (ja) | 2010-06-25 | 2021-12-03 | 治療薬のｃｎｓ送達 |
| JP2023014814A Active JP7543459B2 (ja) | 2010-06-25 | 2023-02-02 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2023024170A Pending JP2023062114A (ja) | 2010-06-25 | 2023-02-20 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2023078673A Pending JP2023099216A (ja) | 2010-06-25 | 2023-05-11 | 治療薬のｃｎｓ送達 |
| JP2024069806A Ceased JP2024097029A (ja) | 2010-06-25 | 2024-04-23 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
Country Status (24)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007285763B2 (en) | 2006-08-18 | 2011-12-15 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| CA3184105A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| BR112012033214B1 (pt) | 2010-06-25 | 2020-11-03 | Shire Human Genetic Therapies, Inc. | uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente |
| JP6045493B2 (ja) | 2010-06-25 | 2016-12-14 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| US20220133863A1 (en) * | 2010-06-25 | 2022-05-05 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| CA2803166C (en) | 2010-06-25 | 2023-03-07 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| US8486399B2 (en) | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| US9682129B2 (en) * | 2011-12-23 | 2017-06-20 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| JP2016523835A (ja) * | 2013-05-15 | 2016-08-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入 |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| CA2985235A1 (en) | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
| HK1258054A1 (zh) * | 2015-12-30 | 2019-11-01 | 株式会社绿十字 | 用於治疗亨特综合征的方法和组合物 |
| EP3419651B1 (en) * | 2016-02-24 | 2023-10-25 | BioMarin Pharmaceutical Inc. | Improved naglu fusion protein formulation |
| US11253612B2 (en) | 2016-04-15 | 2022-02-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type II |
| EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| TW202513090A (zh) | 2018-02-28 | 2025-04-01 | 日商生化學工業股份有限公司 | 醫藥組成物、包裝體及其製造方法 |
| EP4512425A3 (en) * | 2018-02-28 | 2025-05-21 | Seikagaku Corporation | Package and method for producing the same |
| CN108534695A (zh) * | 2018-05-04 | 2018-09-14 | 无锡恩特卫自动化检测设备有限公司 | 一种基于机器视觉系统的瓶塞漏酒检测方法及装置 |
| KR102671857B1 (ko) * | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
| CN112566652A (zh) | 2018-06-25 | 2021-03-26 | Jcr制药股份有限公司 | 含有蛋白的水性液体制剂 |
| JP7253771B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
| JP7253770B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| CN113283465B (zh) * | 2021-04-02 | 2022-04-29 | 电子科技大学 | 一种弥散张量成像数据分析方法及装置 |
| EP4359425B1 (en) | 2021-06-21 | 2026-08-05 | Juvena Therapeutics, Inc. | Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury |
| CN115116623A (zh) * | 2022-06-28 | 2022-09-27 | 深圳市儿童医院 | 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端 |
| AU2024337423A1 (en) * | 2023-09-07 | 2026-03-19 | Juvena Therapeutics, Inc. | Igf2 fusion protein formulations and therapeutic uses thereof |
| EP4788800A1 (en) * | 2023-10-02 | 2026-08-12 | Neurona Therapeutics Inc. | Methods of treating seizure activity |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133001A (en) * | 1959-11-26 | 1964-05-12 | Muset Pedro Puig | Stabilization of enzymes |
| US4743265A (en) | 1986-04-23 | 1988-05-10 | Dij Catheter Corp | Articulated catheter placement device |
| US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
| US5488034A (en) * | 1993-02-02 | 1996-01-30 | Xoma Corporation | Pharmaceutical composition comprising BPI proteins |
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| AUPN674895A0 (en) | 1995-11-23 | 1995-12-14 | Women's And Children's Hospital | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same |
| ES2185117T3 (es) | 1997-08-22 | 2003-04-16 | Seikagaku Kogyo Co Ltd | Agente terapeutico para disco intervertebral herniado. |
| DK2020438T3 (en) | 1998-12-07 | 2018-07-23 | Genzyme Corp | Treatment of Pompe disease |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6368315B1 (en) | 1999-06-23 | 2002-04-09 | Durect Corporation | Composite drug delivery catheter |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US20020099025A1 (en) * | 1999-12-30 | 2002-07-25 | Heywood James A. | Treatment of neurological disorders |
| US6866844B2 (en) * | 2002-11-07 | 2005-03-15 | Biomarin Pharmaceutical Inc. | Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2003102583A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US20030040479A1 (en) | 2001-07-02 | 2003-02-27 | Omeros Corporation | Rotational intrathecal analgesia method and device |
| WO2003032913A2 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US20030181426A1 (en) | 2002-02-11 | 2003-09-25 | Eisenach James C. | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
| DK1503788T3 (da) * | 2002-04-25 | 2011-10-17 | Shire Human Genetic Therapies | Behandling af alpha-galactosidase A-deficiens |
| AU2003299471A1 (en) | 2002-05-07 | 2004-05-13 | Kai Kroll | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
| EP1426069A1 (en) | 2002-12-02 | 2004-06-09 | Diana Evelyn Miller | Drug delivery system |
| PT1587923E (pt) | 2003-01-22 | 2011-12-07 | Univ Duke | Construções melhoradas para a expressão de polipéptidos lisossomais |
| JP5589165B2 (ja) | 2003-01-31 | 2014-09-17 | マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー | タンパク質欠損性障害の治療のための併用療法 |
| CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
| CA2515603C (en) | 2003-02-10 | 2016-06-07 | To-Bbb Holding B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
| WO2005002515A2 (en) | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| NZ576986A (en) | 2004-01-30 | 2010-12-24 | Shire Pharmaceuticals Ireland Ltd | Production and purification of recombinant arylsulfatase A |
| WO2005074888A2 (en) | 2004-02-03 | 2005-08-18 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
| US20080014188A1 (en) | 2004-02-06 | 2008-01-17 | Zankel Todd C | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| UA11577U (en) | 2004-04-21 | 2006-01-16 | Academician A P Romodanov Inst | Device for intrathecal drug administration into spinal canal |
| RU2006144851A (ru) * | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
| DE602005018226D1 (de) * | 2004-08-11 | 2010-01-21 | Basf Se | Zeit-temperatur-indikator auf enzymbasis |
| IL165334A0 (en) * | 2004-11-22 | 2006-01-15 | Mediwound Ltd | Debriding composition from bromelain and methods of producing same |
| EP1889628B1 (en) * | 2005-05-11 | 2013-12-11 | JCR PHARMACEUTICALS Co., LTD. | Lipid liposome composition |
| ES2485369T3 (es) | 2005-06-08 | 2014-08-13 | Amicus Therapeutics, Inc. | Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas |
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| CN101404927A (zh) * | 2006-02-09 | 2009-04-08 | 建新公司 | 慢速脑室内递送 |
| CN101410408A (zh) * | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | 用于浓缩多肽的方法 |
| NO347673B1 (no) | 2006-04-04 | 2024-02-19 | Takeda Pharmaceuticals Co | En sammensetning som omfatter konsentrert polypeptide og bruk derav. |
| GB0611463D0 (en) | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
| US20080076120A1 (en) | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| US8419710B2 (en) * | 2006-12-06 | 2013-04-16 | Medtronic, Inc. | Methods for infusing fluids via an implantable infusion system |
| WO2008109677A2 (en) | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
| JP5341756B2 (ja) | 2007-06-29 | 2013-11-13 | 国立大学法人名古屋大学 | 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤 |
| WO2009017005A1 (ja) | 2007-07-27 | 2009-02-05 | Sharp Kabushiki Kaisha | 移動局装置、基地局装置、通信システム及びプログラム |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| EP2223934B1 (en) * | 2007-11-14 | 2012-10-03 | Institute Of Microbiology, Chinese Academy Of Sciences | Polypeptides for inhibiting influenza virus infection |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| PL3219795T3 (pl) | 2008-01-18 | 2024-09-16 | Biomarin Pharmaceutical Inc. | Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania |
| US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| WO2009131698A2 (en) | 2008-04-23 | 2009-10-29 | Iowa State University Research Foundation, Inc. | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF |
| WO2009137721A2 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| US8436489B2 (en) | 2009-06-29 | 2013-05-07 | Lightsail Energy, Inc. | Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange |
| KR20130043165A (ko) | 2010-06-25 | 2013-04-29 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| JP6045493B2 (ja) | 2010-06-25 | 2016-12-14 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| BR112012033214B1 (pt) | 2010-06-25 | 2020-11-03 | Shire Human Genetic Therapies, Inc. | uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente |
| EP2588132A4 (en) | 2010-06-25 | 2014-10-15 | Shire Human Genetic Therapies | METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS |
| CN103269709A (zh) | 2010-06-25 | 2013-08-28 | 夏尔人类遗传性治疗公司 | Sanfilippo综合症类型B的治疗 |
| CA2803166C (en) * | 2010-06-25 | 2023-03-07 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2012062312A (ja) | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
| US8580922B2 (en) * | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| WO2016025523A1 (en) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
| WO2016025519A1 (en) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| WO2016065319A1 (en) | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
| US9673835B1 (en) | 2015-12-04 | 2017-06-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Pipelined SAR with TDC converter |
-
2011
- 2011-06-25 BR BR112012033214-7A patent/BR112012033214B1/pt active IP Right Grant
- 2011-06-25 CN CN201610569581.XA patent/CN106139133B/zh active Active
- 2011-06-25 HU HUE11799035A patent/HUE031036T2/en unknown
- 2011-06-25 SI SI201131959T patent/SI3103469T1/sl unknown
- 2011-06-25 PT PT117990358T patent/PT2588130T/pt unknown
- 2011-06-25 RS RS20210291A patent/RS61683B1/sr unknown
- 2011-06-25 ES ES16179150T patent/ES2858726T3/es active Active
- 2011-06-25 CA CA3171308A patent/CA3171308A1/en active Pending
- 2011-06-25 UA UAA201507719A patent/UA125060C2/uk unknown
- 2011-06-25 HR HRP20211660TT patent/HRP20211660T1/hr unknown
- 2011-06-25 PE PE2012002474A patent/PE20130578A1/es not_active Application Discontinuation
- 2011-06-25 UA UAA201507529A patent/UA125743C2/uk unknown
- 2011-06-25 HU HUE16179150A patent/HUE052944T2/hu unknown
- 2011-06-25 HU HUE19192508A patent/HUE056884T2/hu unknown
- 2011-06-25 HR HRP20211520TT patent/HRP20211520T1/hr unknown
- 2011-06-25 RS RS20211359A patent/RS62620B1/sr unknown
- 2011-06-25 PE PE2018000183A patent/PE20180801A1/es unknown
- 2011-06-25 PT PT117990374T patent/PT2585104T/pt unknown
- 2011-06-25 NZ NZ702803A patent/NZ702803A/en unknown
- 2011-06-25 PT PT117990366T patent/PT2593131T/pt unknown
- 2011-06-25 NZ NZ702800A patent/NZ702800A/en not_active IP Right Cessation
- 2011-06-25 DK DK19192508.0T patent/DK3626257T3/da active
- 2011-06-25 PE PE2017001612A patent/PE20180130A1/es unknown
- 2011-06-25 PE PE2012002476A patent/PE20130589A1/es not_active Application Discontinuation
- 2011-06-25 LT LTEP19192508.0T patent/LT3626257T/lt unknown
- 2011-06-25 DK DK19192679.9T patent/DK3626258T3/da active
- 2011-06-25 ES ES19192508T patent/ES2896060T3/es active Active
- 2011-06-25 PT PT161791504T patent/PT3103469T/pt unknown
- 2011-06-25 HU HUE11799037A patent/HUE046409T2/hu unknown
- 2011-06-25 ES ES19192679T patent/ES2895655T3/es active Active
- 2011-06-25 CN CN201610086722.2A patent/CN105664142A/zh active Pending
- 2011-06-25 PE PE2017000503A patent/PE20170938A1/es unknown
- 2011-06-25 HU HUE11799036A patent/HUE046856T2/hu unknown
- 2011-06-25 MX MX2013000321A patent/MX354776B/es active IP Right Grant
- 2011-06-25 RS RS20211191A patent/RS62520B1/sr unknown
- 2011-06-25 SI SI201132007T patent/SI3626258T1/sl unknown
- 2011-06-25 PT PT191926799T patent/PT3626258T/pt unknown
- 2011-06-25 CN CN201510512218.XA patent/CN105233277B/zh active Active
- 2011-06-25 HU HUE19192679A patent/HUE055963T2/hu unknown
- 2011-06-25 PT PT191925080T patent/PT3626257T/pt unknown
- 2011-06-25 CN CN201510172262.0A patent/CN104857504A/zh active Pending
- 2011-06-25 RU RU2017125281A patent/RU2761342C2/ru active
- 2011-06-25 PE PE2012002479A patent/PE20130637A1/es not_active Application Discontinuation
- 2011-06-25 DK DK16179150.4T patent/DK3103469T3/da active
- 2011-06-25 PL PL11799035T patent/PL2588130T3/pl unknown
- 2011-06-25 LT LTEP16179150.4T patent/LT3103469T/lt unknown
- 2011-06-25 PE PE2012002475A patent/PE20130579A1/es active IP Right Grant
- 2011-06-25 SI SI201132014T patent/SI3626257T1/sl unknown
- 2011-06-25 PE PE2012002498A patent/PE20130648A1/es not_active Application Discontinuation
- 2011-06-25 LT LTEP19192679.9T patent/LT3626258T/lt unknown
- 2011-06-25 UA UAA201507721A patent/UA129740C2/uk unknown
- 2011-06-27 TW TW106127273A patent/TWI698252B/zh active
- 2011-06-27 TW TW112102995A patent/TWI876260B/zh active
- 2011-06-27 TW TW106135183A patent/TWI669128B/zh active
- 2011-06-27 TW TW109118555A patent/TWI790444B/zh active
- 2011-06-27 AR ARP110102244A patent/AR081680A1/es unknown
- 2011-06-27 AR ARP110102241A patent/AR081677A1/es not_active Application Discontinuation
- 2011-06-27 AR ARP110102246A patent/AR082025A1/es not_active Application Discontinuation
- 2011-06-27 TW TW100122534A patent/TWI602573B/zh active
- 2011-06-27 AR ARP110102243A patent/AR081679A1/es unknown
- 2011-06-27 TW TW105115109A patent/TW201701899A/zh unknown
- 2011-06-27 TW TW113122692A patent/TW202506172A/zh unknown
- 2011-06-27 AR ARP110102242A patent/AR081678A1/es not_active Application Discontinuation
- 2011-06-27 TW TW100122529A patent/TW201212936A/zh unknown
- 2011-06-27 TW TW106108970A patent/TWI609694B/zh active
- 2011-06-27 AR ARP110102245A patent/AR081681A1/es unknown
-
2012
- 2012-12-21 CL CL2012003656A patent/CL2012003656A1/es unknown
- 2012-12-21 CL CL2012003655A patent/CL2012003655A1/es unknown
- 2012-12-21 CL CL2012003657A patent/CL2012003657A1/es unknown
- 2012-12-21 CL CL2012003654A patent/CL2012003654A1/es unknown
-
2013
- 2013-05-10 US US13/892,076 patent/US9814764B2/en active Active
- 2013-08-23 US US13/974,457 patent/US9220677B2/en active Active
-
2015
- 2015-11-11 US US14/938,824 patent/US20160158324A1/en not_active Abandoned
- 2015-12-03 JP JP2015236539A patent/JP6250616B2/ja active Active
- 2015-12-17 JP JP2015246244A patent/JP6285409B2/ja active Active
- 2015-12-17 JP JP2015246589A patent/JP2016094451A/ja active Pending
- 2015-12-17 JP JP2015246258A patent/JP2016040335A/ja not_active Withdrawn
- 2015-12-18 JP JP2015246952A patent/JP6346162B2/ja active Active
-
2016
- 2016-02-04 US US15/016,141 patent/US10456454B2/en active Active
- 2016-02-25 HK HK16102145.2A patent/HK1214149A1/zh unknown
- 2016-03-22 US US15/077,046 patent/US20170042977A1/en not_active Abandoned
- 2016-10-27 SM SM201600385T patent/SMT201600385B/it unknown
- 2016-12-07 CL CL2016003159A patent/CL2016003159A1/es unknown
-
2017
- 2017-08-23 US US15/684,568 patent/US10646554B2/en active Active
- 2017-09-15 JP JP2017177784A patent/JP6466538B2/ja active Active
- 2017-09-26 US US15/715,748 patent/US11065307B2/en active Active
- 2017-10-03 CL CL2017002488A patent/CL2017002488A1/es unknown
- 2017-10-04 JP JP2017194348A patent/JP6522072B2/ja active Active
- 2017-10-04 JP JP2017194508A patent/JP6522073B2/ja active Active
-
2018
- 2018-07-16 US US16/036,584 patent/US11065308B2/en active Active
- 2018-10-11 JP JP2018192589A patent/JP6797876B2/ja active Active
- 2018-12-03 JP JP2018226358A patent/JP6898909B2/ja active Active
- 2018-12-04 JP JP2018227369A patent/JP6938456B2/ja active Active
-
2019
- 2019-07-18 US US16/515,568 patent/US11260112B2/en active Active
- 2019-09-17 US US16/573,557 patent/US11471516B2/en active Active
-
2020
- 2020-01-07 JP JP2020000930A patent/JP2020079244A/ja not_active Withdrawn
- 2020-02-14 JP JP2020023620A patent/JP2020079297A/ja active Pending
- 2020-02-17 JP JP2020024183A patent/JP2020079298A/ja active Pending
- 2020-02-26 CL CL2020000468A patent/CL2020000468A1/es unknown
- 2020-03-24 US US16/828,731 patent/US12168041B2/en active Active
-
2021
- 2021-02-23 HR HRP20210298TT patent/HRP20210298T1/hr unknown
- 2021-06-17 US US17/350,860 patent/US12161702B2/en active Active
- 2021-07-13 JP JP2021115564A patent/JP7087175B2/ja active Active
- 2021-07-13 JP JP2021115560A patent/JP7448507B2/ja active Active
- 2021-08-18 JP JP2021133184A patent/JP7591476B2/ja active Active
- 2021-12-03 JP JP2021196898A patent/JP7359827B2/ja active Active
-
2022
- 2022-01-18 US US17/578,119 patent/US12121569B2/en active Active
- 2022-08-16 US US17/820,155 patent/US12409210B2/en active Active
-
2023
- 2023-02-02 JP JP2023014814A patent/JP7543459B2/ja active Active
- 2023-02-20 JP JP2023024170A patent/JP2023062114A/ja active Pending
- 2023-05-11 JP JP2023078673A patent/JP2023099216A/ja active Pending
-
2024
- 2024-04-23 JP JP2024069806A patent/JP2024097029A/ja not_active Ceased
- 2024-09-19 US US18/890,181 patent/US20250121040A1/en active Pending
- 2024-10-29 US US18/930,737 patent/US20250161417A1/en active Pending
-
2025
- 2025-08-15 US US19/301,198 patent/US20250375506A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542913A5 (cg-RX-API-DMAC10.html) | ||
| US11124781B2 (en) | P97-IDS fusion proteins | |
| JP2016040335A5 (cg-RX-API-DMAC10.html) | ||
| US9192649B2 (en) | Annexin and its use to treat inflammatory disorders | |
| CN104039811B (zh) | 具有改善的细胞渗透性的新的大分子转导结构域的研发及其使用方法 | |
| US20200048324A1 (en) | Tissue-specific wnt signal enhancing molecules and uses thereof | |
| JP6794409B2 (ja) | シータデフェンシンによる炎症性プロテアーゼの遮断 | |
| TWI873177B (zh) | 治療性融合蛋白 | |
| WO2011157713A4 (en) | Cell-penetrating peptides and uses therof | |
| JP2018516566A (ja) | 病的石灰化状態を治療するための組成物およびそれを使用する方法 | |
| JP2010516290A5 (cg-RX-API-DMAC10.html) | ||
| JP2012509071A5 (cg-RX-API-DMAC10.html) | ||
| JP2011504366A5 (cg-RX-API-DMAC10.html) | ||
| US20170029798A1 (en) | Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD) | |
| JP2011528222A5 (cg-RX-API-DMAC10.html) | ||
| US12428445B2 (en) | Mini-nucleosome core proteins and use in nucleic acid delivery | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| CA3205570A1 (en) | Fusion molecule having non-inflammatory phagocytosis inducing activity | |
| CN106279439A (zh) | 一种含有穿膜肽的寡肽‑1融合蛋白及其制备方法 | |
| JP2020037538A (ja) | アンジオテンシン変換酵素２活性を有する原核微生物由来ポリペプチドの医薬用途 | |
| CA2882763A1 (en) | Aav mediated aquaporin gene transer to treat sjogren's syndrome | |
| CN115427428A (zh) | 新的细胞穿透肽及其用途 | |
| JP2019503171A5 (cg-RX-API-DMAC10.html) | ||
| WO2012104462A1 (es) | Heptapéptidos y su uso para el control de la hipertensión | |
| US20150165013A1 (en) | Composition for use in mycobacteria vaccination |